The lesion detection capability and clinical effectiveness of dual-head coincidence gamma camera imaging (c-PET) were compared with those of dedicated positron emission tomography (d-PET) in 37 cancer patients who underwent whole-body c-PET and d-PET imaging after administration of 370 -540 MBq 18 F-fluorodeoxyglucose. Eighty-nine lesions were detected on c-PET whereas 133 lesions were seen with d-PET imaging. The relative sensitivity of c-PET compared with d-PET was 62% and 73% for lesions < 15 and ≥ 15 mm, respectively, and the relative concordance rate was 84% when the patients were restaged. Since the lesion detection rate of c-PET imaging was lower than that of d-PET, the detection of small lesions, therefore, requires care. The clinical effectiveness of c-PET, however, was similar to that of d-PET and, therefore, it is concluded that c-PET can be used as an alternative to d-PET, particularly considering the high cost and limited availability of d-PET cameras.
Introduction
Positron emission tomography (PET) has an established role in the diagnosis, staging/restaging, treatment monitoring and early detection of recurrence in tumour patients. 1 -3 The complexity of on-site synthesis of PET radiopharmaceuticals, their high cost, and the operation and maintenance expenses of a full-ring dedicated system preclude the widespread use of PET. A cyclotron accelerator system now exists, however, with automated synthesis and a well-organized delivery system, that exploits the 109-min half-life of 18 F-fluorodeoxyglucose ( 18 F-FDG) for PET studies. In addition, recently, several manufacturers have developed dual-head gamma camera systems capable of detecting Y Narin, M Urhan, N Canpolat et al. Dual-head coincidence gamma camera imaging two annihilation photons in coincidence mode (c-PET). These camera systems are less expensive than dedicated PET (d-PET) cameras and hold promise for conventional imaging as well as potentially making 18 F-FDG PET available to most nuclear medicine departments.
The basic clinical performance characteristics of c-PET systems are similar to those of d-PET, although a lower detection efficiency and spatial resolution has been reported. 4 -8 An alternative is to use thicker sodium iodide (NaI) crystals in coincidence gamma cameras to increase their efficiency in stopping high-energy gamma rays like the 511 keV photons of 18 F-FDG. 9 In this prospective study in tumour patients we evaluated the lesion detectability and clinical effectiveness of c-PET with a 5/8 inch (16 mm) thick NaI crystal in coincidence mode, compared with 18 F-FDG PET imaging with a d-PET system.
Patients and methods

PATIENTS
Thirty-seven patients (22 males, 15 females; mean age 63 years, range 22 -82 years) with a proven malignant tumour were enrolled in the study. No ethics approval was required because FDG-PET imaging was requested by the referring primary care physician of each patient as a part of their clinical evaluation. A written informed consent had been obtained from all patients regarding the need for two images rather than the usual one. All patients underwent anatomical imaging with ultrasonography, computed tomography (CT) or magnetic resonance imaging (MRI) before the PET study. Patients with diabetes or glucose intolerance were excluded from the study. Blood glucose levels were measured by a capillary sampling method and patients with a level ≥ 140 mg/dl were excluded from the study.
18
F-FDG PET IMAGING
The patients fasted for at least 8 h before the PET study, after which each patient received approximately 370 -540 MBq 18 F-FDG intravenously. The c-PET study was performed 45 min after 18 F-FDG administration using a dual-head gamma camera in coincidence detection mode and a 5/8 inch (16 mm) thick NaI (Tl) crystal (E.Cam™, Siemens, Knoxville, TN, USA). Emission scans with two-or three-bed positions, including the head and neck, thorax and abdomen/pelvis, were obtained with an acquisition time of 45 min for each position. The images were reconstructed with the ordered subset expectation maximization (OS-EM) algorithm (two iterations with six ordered subsets). The fullwidth half-maximum (FWHM) was 13.1 mm on the reconstructed images. No attenuation correction was performed.
After c-PET imaging a d-PET study (ECAT ® EXACT™ ART scanner; Siemens) was performed, this being undertaken 150 -180 min after 18 F-FDG injection. Emission scans were acquired in three-dimensional mode and corrected for attenuation with an external radioactive source of 137 Cs. The acquisition time was 10 min (7 min for emission and 3 min for transmission) for each bed position and images were taken from the head to the proximal femora. The data were reconstructed with an iterative reconstruction algorithm (OS-EM).
The images were analysed by four independent observers in a totally blind and random fashion on a computer monitor in the transaxial, coronal and sagittal planes. The c-PET images were evaluated first, followed by the d-PET whole-body scans. The regions with abnormal 18 F-FDG activity were correlated with CT, MRI or ultrasonographic data, but the sensitivity and diagnostic accuracy of PET imaging versus anatomical Y Narin, M Urhan, N Canpolat et al.
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imaging modalities was not assessed. Lesions were classified on the basis of size (< 15 and ≥ 15 mm) and the location of abnormal 18 F-FDG accumulation (head and neck, thorax, abdomen, pelvis).
A positive result was when abnormal 18 F-FDG accumulation was detected on the PET images. The clinical management of patients was not influenced by the number of 18 F-FDG accumulating lesions at a particular anatomical site, therefore c-PET and d-PET images were considered concordant as long as at least one common pathological lesion was seen at the same site in both images.
Results
Histopathology of the tumour showed primary and/or recurrent lung cancer in 13 of the 37 patients enrolled in the study, thyroid carcinoma (one undifferentiated, one follicular, one papillary and three medullary) in six patients, breast cancer in three, hepatocellular carcinoma in two, rectum carcinoma in two and various tumours including endometrium, Ewing, carcinoid, colon, leiomyosarcoma, malignant melanoma, bladder, prostate, stomach, pancreas and testis carcinoma in 11 patients.
Lesion-based comparisons showed that a total of 133 abnormal lesions were detected by d-PET imaging (12 in the head and neck region, 81 in the thorax, 19 in the abdomen and 21 in the pelvis). Of these 133 lesions, 89 (67%) were also detected on c-PET imaging (six lesions in the head and neck, 57 in the thorax, 12 in the abdomen and 14 in the pelvis). The size of the lesions ranged from 7 to 80 mm. Of those lesions detected by d-PET that were < 15 mm or ≥ 15 mm, 62% and 73%, respectively, were also detected by c-PET. The distribution of the lesions by size and location is shown in Table 1 . At least one abnormal 18 F-FDG accumulation appeared at the same site in both c-PET and d-PET images in 31 out of 37 patients, hence the concordance rate of the procedures was calculated to be 84%.
The relative frequency of the 18 F-FDG accumulating hypermetabolic lesions detected by c-PET compared with d-PET according to anatomical site is shown in Table 2 . It can be seen that this varied depending on the anatomical location of the lesions. In areas of good lesion/background activity, such as the lungs, the detection rate by c-PET compared with d-PET was good (concordance 89%), whereas in other areas, such as bone, liver and lymph nodes it was lower (54%, 60% and 64%, respectively). The clinical relevance of data from other areas including the surrenal (2) and pancreas were irrelevant owing to the small sample size.
In terms of the clinical effectiveness and management of patients, any abnormal Figure 1 shows the example of a 65-year-old female patient with non-small cell lung cancer in whom increased 18 F-FDG uptake in the right lung was seen on coronal images from both c-PET and d-PET scanning. Of 37 patients, 29 were evaluated for staging/restaging and eight for diagnostic purposes. Upstaging was noted in 14 patients after evaluating c-PET images, compared with 17 patients when d-PET was used. The three patients for whom there was discordance comprised two patients with lung cancer and one patient with bladder carcinoma with additional bone metastases in the vertebral column. 
TABLE 2: Numbers of hypermetabolic lesions detected by dual-head coincidence gamma camera imaging positron emission tomography (c-PET) compared with dedicated PET (d-PET) imaging in patients with malignant tumours
Discussion
The high cost of a full-ring dedicated PET scanner and cyclotron has been the major constraint on worldwide clinical use of PET. Using PET with a modified gamma camera, however, offers a cost-effective alternative to dedicated systems, especially in tumour patients for initial diagnosis, staging/restaging and monitoring treatment response. The aim of this study was to assess the performance of c-PET imaging in comparison a d-PET system. A large amount of data on the clinical use of c-PET in patients with a range of different malignancies has been published, including reports that the lesion detection rate of c-PET is inferior to that of d-PET, yet also that the overall correlation of both procedures is good in terms of clinical effectiveness and disease staging. 10, 11 In the present study, the c-PET method detected 62% and 73% of the smaller and larger lesions, respectively, that were detected by d-PET. The probability of detecting smaller lesions on c-PET imaging appeared to be lower than with d-PET systems because of limited spatial resolution, lower image contrast and partial volume effects. Limited spatial resolution is due to the lower count rate and lower detection of coincidence events with c-PET systems compared with d-PET systems. 12 More 18 F-FDG activity can be administered to increase the number of events reaching the dual-head camera; however, oversaturation may significantly diminish the system's efficiency and must be avoided.
Image contrast is another factor limiting spatial resolution and the lesion detection rate on c-PET images. Contrast has been reported to be 32% lower in c-PET imaging compared with d-PET systems and may even be 60% lower for small lesions. 13 Use of an attenuation correction protocol with a dual-head coincidence gamma camera may improve imaging and has been reported to increase the sensitivity of attenuationcorrected c-PET images from 60% to 80% for lesions < 2 cm. 14 In addition to lesion size, the avidity of 18 F-FDG is another factor to be considered; small lesions with intense 18 F-FDG avidity can be detected by c-PET, whereas lesions ≥ 15 mm with intense 18 F-FDG avidity cannot be identified on c-PET images.
In the present study lesions were classified according to their size and areas on the body regions where abnormal 18 F-FDG accumulations appeared. On the head and neck, six hypermetabolic lesion sites (five lesions < 15 mm and one lesion ≥ 15 mm) were detected on c-PET images compared with 12 lesions (11 lesions < 15 mm and one lesion ≥ 15 mm) identified on d-PET images. This poor correlation was mainly considered to be due to the small lesion size of metastatic lymph nodes occurring in the neck. Adding attenuation correction to c-PET may improve identification of lesions that are close to physiologically hypermetabolic areas, such as the larynx and neck muscles. The present study showed that the overall sensitivity of c-PET imaging was 89% in detecting pulmonary lesions whereas it was 64% for lymph nodes and 54% for bone metastases. Shreve et al. 15 reported that the sensitivity of c-PET compared with d-PET was 93% for lung nodules and masses, 65% for mediastinal, 71% for neck and 55% for axillary lymph nodes, and 50% for bone metastases. In both studies there was a relatively high concordance in detecting hypermetabolic lesions in areas of good lesion/background activity, such as in the lungs, while there was a considerable discrepancy in detecting bone metastases.
The high background noise of surrounding tissues may decrease the Y Narin, M Urhan, N Canpolat et al. Dual-head coincidence gamma camera imaging resolution as a result of scatter and cause a reduction in sensitivity. The same explanation may apply to the difference in lesion detection seen between c-PET and d-PET in the abdominal/pelvic region. Of the 40 hypermetabolic lesions detected in the abdominal/pelvic region by the present study with the d-PET system, 26 (65%) were also identified on c-PET images. Identification of lesions is problematic in this area because of the physiological distribution of 18 F-FDG in the abdomen, with high background activity occurring in the liver and bladder. Attenuation correction may improve visualization of liver and abdominal lesions, including deep-seated lesions such as those in the lumboaortic lymph nodes and vertebral bone metastases.
Kubota et al. 16 reported that more lesions can be identified by delaying PET imaging after 18 F-FDG injection because of the improved tumour/background ratio. In our study, 18 F-FDG PET imaging was performed approximately 45 and 150 -180 min after FDG injection with c-PET and d-PET, respectively. This may have contributed to a lowered sensitivity for c-PET compared with d-PET.
In conclusion, the present study showed the lesion detection rate of c-PET imaging to be inferior to that of d-PET, especially for lesions < 15 mm, so caution needs to be exercised in the detection of small lesions by this method. Implementation of an attenuation correction may improve resolution and lesion detectability. The clinical effectiveness of c-PET imaging was, however, still considered to be comparable with that of a d-PET system. Owing to the high cost and limited availability of d-PET systems we consider c-PET imaging to be a viable alternative PET procedure.
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